Deutsche Bank has Kursziel für Merck KGaA-Aktien Von Investing.com

Deutsche Bank hat ihr Kursziel für Merck (ETR:) KGaA (MRK: GR) (OTC: MKGAF) from € 188.00 to € 180.00, stops after the Kaufempfehlung party.

This analysis is based on the background, while the future of the future makes the best predictions for 2024, allowing one of the best performances in the Life-Science segment. Here with an Auslaufrate of 6%gericht, one of the forecasts of 7-10% was lying.

The Deutschen Bank analyst took into account that Merck would start work a year later in 2025. It doesn’t take long before the Fokus goes further than most people who lie about Life-Science-Geschäft.

It is always the case that market forces are possible for these segments. Please note that it is important to know that investors are aware of the fact that the moderate forecast for the pharmaceutical industry will be reflected in the product pipeline and that the future will be corrected. There was a German Abweichung because there were some simple insights into the Wachstum.

It is possible that the world from a statutory financing of an industry association will put a stop to the development of the Life-Science segments and Chinese market signaling.

The information provided is that Merck makes a mediocre forecast for the Life-Science segment on a waiting list of 6-9% after a corrective world. That’s one of the few risks you can expect from a 7-10% forecast.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.